| Variable |
CYFRA 21-1(ng/ml) |
P-value |
CEA (ng/ml) |
P-value |
| Type of NSCLC |
| Squamous cell (n=18) |
16.21 ± 16.6 |
0.03 |
6.49 ± 9.3 |
0.01 |
| Adenocarcinoma (n=22) |
4.63 ± 3.31 |
60.2 ± 79.4 |
| Stage of NSCLC |
| Stage II (n=7) |
3.45 ± 4.98 |
0.001 |
3.65 ± 4.46 |
0.005 |
| Stage III (n=24) |
8.91 ± 9.17 |
12.01 ± 17.6 |
| Stage IV (n=9) |
28.32 ± 12.58 |
81.4 ± 77.01 |
| Performance status |
| <2(n=25) |
3.49 ± 2.26 |
0.01 |
3.48 ± 2.97 |
0.001 |
| ≥ 2(n=15) |
21.95 ± 15.02 |
79.89 ± 78.79 |
| Sex |
| Males (n=30) |
6.88 ± 7.49 |
0.44 |
29.01 ± 61.18 |
0.98 |
| Females (n=10) |
15.86 ± 19.27 |
25.55 ± 39.58 |
|
